Heart, Lung and Circulation最新文献

筛选
英文 中文
Shunt or Primary Repair in Symptomatic Neonates With Tetralogy of Fallot: The Time has Come for a Randomised Trial to Settle the Debate 有症状的法洛四联症新生儿的分流或初级修复:是时候进行随机试验来解决这个争论了
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.08.007
William Foot MBBS, Nelson Alphonso FRACS, Prem Venugopal FRACS
{"title":"Shunt or Primary Repair in Symptomatic Neonates With Tetralogy of Fallot: The Time has Come for a Randomised Trial to Settle the Debate","authors":"William Foot MBBS, Nelson Alphonso FRACS, Prem Venugopal FRACS","doi":"10.1016/j.hlc.2025.08.007","DOIUrl":"10.1016/j.hlc.2025.08.007","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 873-874"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Symptomatic Neonates With Tetralogy of Fallot: Shunt or Primary Repair? 有症状的新生儿法洛四联症:分流还是初级修复?
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.01.009
Xin Tao Ye MD , Soichiro Henmi MD, PhD , Edward Buratto MBBS, PhD , Mitchell C. Haverty MS , Can Yerebakan MD , Tyson Fricke MBBS, PhD , Christian P. Brizard MD, MS , Yves d’Udekem MD, PhD , Igor E. Konstantinov MD, PhD
{"title":"Symptomatic Neonates With Tetralogy of Fallot: Shunt or Primary Repair?","authors":"Xin Tao Ye MD ,&nbsp;Soichiro Henmi MD, PhD ,&nbsp;Edward Buratto MBBS, PhD ,&nbsp;Mitchell C. Haverty MS ,&nbsp;Can Yerebakan MD ,&nbsp;Tyson Fricke MBBS, PhD ,&nbsp;Christian P. Brizard MD, MS ,&nbsp;Yves d’Udekem MD, PhD ,&nbsp;Igor E. Konstantinov MD, PhD","doi":"10.1016/j.hlc.2025.01.009","DOIUrl":"10.1016/j.hlc.2025.01.009","url":null,"abstract":"<div><h3>Background</h3><div>The optimal management strategy for symptomatic neonates with tetralogy of Fallot is unclear. We compared the outcomes of staged repair (SR) (shunt palliation followed by complete repair) and primary repair (PR) in two institutions that have each exclusively adopted one of these strategies.</div></div><div><h3>Method</h3><div>We retrospectively compared 65 symptomatic neonates who underwent shunt palliation between 1993 and 2021 at the Royal Children’s Hospital, Melbourne, Australia with 38 symptomatic neonates who underwent PR between 2005 and 2018 at the Children’s National Hospital, Washington, USA. Median follow-up duration was 8.0 (interquartile range 2.9–13.5) years.</div></div><div><h3>Results</h3><div>After the initial procedure, hospital mortality (shunt 4.6% vs PR 7.9%; p=0.50) and 5-year survival (shunt 94%; 95% confidence interval [CI] 84%–98% vs PR 89%; 95% CI 72%–96%; p=0.21) were not significantly different. The SR group had shorter durations of cardiopulmonary bypass and intensive care admission during the neonatal period, but a higher burden of unplanned re-interventions before discharge. Five-year freedom from re-interventions was not significantly different (shunt 63%; 95% CI 49%–74% vs PR 49%; 95% CI 29%–66%; p=0.13). Postoperative morbidity, mortality, and re-interventions were not significantly different among 13 propensity score–matched pairs balanced for operative weight. For neonates weighing &lt;3 kg, PR was associated with significantly more early re-interventions.</div></div><div><h3>Conclusions</h3><div>In symptomatic neonates with tetralogy of Fallot operated at two institutions with distinct treatment protocols, no statistically significant difference in medium-term survival and re-intervention was observed between the two strategies. SR was associated with lower neonatal morbidity but more unplanned re-interventions before discharge. PR in neonates weighing &lt;3 kg may result in more early re-interventions.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 935-950"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Access, Real Impact: Reimagining Chest Pain Clinics for the Australian Healthcare System 快速访问,真正的影响:重新构想胸痛诊所为澳大利亚医疗保健系统
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.08.005
Travis Chong MD, MMed , Nick S.R. Lan MBBS, MClinRes , Girish Dwivedi MD, PhD
{"title":"Rapid Access, Real Impact: Reimagining Chest Pain Clinics for the Australian Healthcare System","authors":"Travis Chong MD, MMed ,&nbsp;Nick S.R. Lan MBBS, MClinRes ,&nbsp;Girish Dwivedi MD, PhD","doi":"10.1016/j.hlc.2025.08.005","DOIUrl":"10.1016/j.hlc.2025.08.005","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 869-872"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145003647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health for Every Heart – the Heart Foundation’s 25-year vision for heart health in Australia 每个心脏的健康-心脏基金会在澳大利亚心脏健康的25年愿景
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.08.004
{"title":"Health for Every Heart – the Heart Foundation’s 25-year vision for heart health in Australia","authors":"","doi":"10.1016/j.hlc.2025.08.004","DOIUrl":"10.1016/j.hlc.2025.08.004","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Page 984"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145005268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteomic Effects of Colchicine on Human Macrophages Loaded With Oxidised Low-Density Lipoprotein Cholesterol 秋水仙碱对装载氧化低密度脂蛋白胆固醇的人巨噬细胞的蛋白质组学影响。
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.04.071
Sushma R. Rao PhD , Thalia Salagaras BSc , Yung-Chih Chen PhD , Christina A. Bursill PhD , Karlheinz Peter MD, PhD , Marten F. Snel PhD , Peter J. Psaltis MBBS, PhD
{"title":"Proteomic Effects of Colchicine on Human Macrophages Loaded With Oxidised Low-Density Lipoprotein Cholesterol","authors":"Sushma R. Rao PhD ,&nbsp;Thalia Salagaras BSc ,&nbsp;Yung-Chih Chen PhD ,&nbsp;Christina A. Bursill PhD ,&nbsp;Karlheinz Peter MD, PhD ,&nbsp;Marten F. Snel PhD ,&nbsp;Peter J. Psaltis MBBS, PhD","doi":"10.1016/j.hlc.2025.04.071","DOIUrl":"10.1016/j.hlc.2025.04.071","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 980-983"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early and Midterm Outcomes of INSPIRIS RESILIA Versus AVALUS: A Propensity Score Matching Analysis 与阿瓦卢斯相比,抗压性脑出血的早期和中期结果:倾向评分匹配分析。
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.02.110
Takuya Narita MD, PhD , Taisuke Nakayama MD, PhD , Shuhei Nishijima MD , Yoshitsugu Nakamura MD, PhD
{"title":"Early and Midterm Outcomes of INSPIRIS RESILIA Versus AVALUS: A Propensity Score Matching Analysis","authors":"Takuya Narita MD, PhD ,&nbsp;Taisuke Nakayama MD, PhD ,&nbsp;Shuhei Nishijima MD ,&nbsp;Yoshitsugu Nakamura MD, PhD","doi":"10.1016/j.hlc.2025.02.110","DOIUrl":"10.1016/j.hlc.2025.02.110","url":null,"abstract":"<div><h3>Objectives</h3><div>To compare the early and midterm clinical outcomes of aortic valve replacement (AVR) using the INSPIRIS RESILIA bioprosthesis (IR-B) with AVR using the AVALUS bioprosthesis (AV-B).</div></div><div><h3>Methods</h3><div>This single-centre retrospective study analysed the perioperative clinical outcomes of 256 consecutive patients who underwent AVR with either IR-B (n=156) or AV-B (n=100) at this institution between 1 August 2018 and 30 June 2023. After propensity score matching, freedom from death, freedom from major adverse cardiovascular events (MACE), and echocardiographic data were compared between the two groups during the follow-up period.</div></div><div><h3>Results</h3><div><span><span>Propensity score matching resulted in the addition of 79 patients to each group. The 1-year survival rates in the propensity score-matched cohort were 93.8% and 94.5% in the IR-B and AV-B groups, respectively, while the 3-year survival rates remained unchanged, with no statistically significant differences between groups (p=0.88). At 3 years postoperatively, freedom from MACE was 93.2% and 92.8% in the IR-B and the AV-B groups, respectively, which was not statistically significant (p=0.90). The mean </span>aortic pressure gradient after AVR remained stable in both the IR-B and AV-B groups (IR-B group, 10.7–11.3 mmHg vs AV-B group, 11.5–12.1 mmHg), and there was no significant difference observed between the two groups during the follow-up period. The absolute change from the baseline left ventricular mass index in both the IR-B and AV-B groups decreased in each group over time (IR-B group, −20.8 to −38.6 g/m</span><sup>2</sup> vs AV-B group, −16.6 to −35.5 g/m<sup>2</sup>). However, these changes were statistically insignificant between the two groups over the 3-year follow-up.</div></div><div><h3>Conclusion</h3><div>The early and midterm clinical outcomes were comparable between the IR-B and AV-B groups.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 908-917"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rapid Progression of Right Ventricular Deterioration and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot 法洛四联症修复后右心室恶化的快速进展和肺动脉瓣置换术的时机。
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.03.014
Xander Jacquemyn BSc , Sruti Rao MD , Ashish N. Doshi MD, PhD , David A. Danford MD , Shelby Kutty MD, PhD, MHCM
{"title":"Rapid Progression of Right Ventricular Deterioration and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot","authors":"Xander Jacquemyn BSc ,&nbsp;Sruti Rao MD ,&nbsp;Ashish N. Doshi MD, PhD ,&nbsp;David A. Danford MD ,&nbsp;Shelby Kutty MD, PhD, MHCM","doi":"10.1016/j.hlc.2025.03.014","DOIUrl":"10.1016/j.hlc.2025.03.014","url":null,"abstract":"<div><h3>Background</h3><div>We aimed to identify a progressive phenotype in repaired tetralogy of Fallot (rTOF), characterised by accelerated changes in right ventricular (RV) parameters on cardiac magnetic resonance (CMR) and assess its association with an accelerated course to pulmonary valve replacement (PVR).</div></div><div><h3>Method</h3><div>This was a retrospective study of patients with rTOF who had two or more CMRs (2005–2022). Clinical variables and CMR data were collected, and annualised changes in CMR data were calculated. “Rapid progressors” were classified as those with annual RV ejection fraction decreases&gt;3.5% or RV end-diastolic volume index (RVEDVi) increases&gt;3.5 mL/m<sup>2</sup>.</div></div><div><h3>Results</h3><div>A total of 112 patients with rTOF (median age 14.7 years, 63 males) were included, with 60 identified as rapid progressors (12 based on RV ejection fraction, 48 based on the RVEDVi criteria). Baseline RV volumes and function were similar between groups, although rapid progressors had a higher pulmonary regurgitant fraction (PRF) (38.2±16.3 vs 31.4±15.4%; p=0.033). Pulmonary regurgitant fraction (PRF) (odds ratio 1.03; 95% confidence interval [CI] 1.00–1.05; p=0.037) and RV end-diastolic volume/left ventricular end-diastolic volume ratio (odds ratio 2.75; 95% CI 1.13–7.35; p=0.032) were significant predictors of the rapid progressive phenotype. During follow-up (median 9.3 years, interquartile range 6.8–13.8), 48 patients underwent PVR. Rapid progressors had a five-fold increased risk of PVR (hazard ratio 5.44; 95% CI 2.75–10.8; p&lt;0.001). Adjusting for age, sex, transannular patch use, baseline RVEDVi, and PRF, the risk of PVR remained over five-fold higher in rapid progressors (hazard ratio 5.18; 95% CI 4.39–5.97; p&lt;0.001).</div></div><div><h3>Conclusions</h3><div>This study identifies imaging biomarkers in the rTOF subpopulation that were more likely to have an early PVR.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 951-960"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fully Loaded: Digoxin Initiation and Monitoring 满载:地高辛起始和监测。
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.04.073
Jinara Devinuwara MD , Pany Virdi MD , Sheryn Tan MD , Ong Sze Tong MD , Jeng Swen Ng MD , Toby Gilbert MB, BCh, BAO , Samuel Gluck BA, MA, MB , Cassandra Potts BPharm , Alice Wisdom BPharm , Mirjana Culibrk BPharm, MClinPharm , Jacinta L. Johnson BPharm, PhD , Lia Bouras BPharm , Stephen Bacchi MBBS, PhD
{"title":"Fully Loaded: Digoxin Initiation and Monitoring","authors":"Jinara Devinuwara MD ,&nbsp;Pany Virdi MD ,&nbsp;Sheryn Tan MD ,&nbsp;Ong Sze Tong MD ,&nbsp;Jeng Swen Ng MD ,&nbsp;Toby Gilbert MB, BCh, BAO ,&nbsp;Samuel Gluck BA, MA, MB ,&nbsp;Cassandra Potts BPharm ,&nbsp;Alice Wisdom BPharm ,&nbsp;Mirjana Culibrk BPharm, MClinPharm ,&nbsp;Jacinta L. Johnson BPharm, PhD ,&nbsp;Lia Bouras BPharm ,&nbsp;Stephen Bacchi MBBS, PhD","doi":"10.1016/j.hlc.2025.04.073","DOIUrl":"10.1016/j.hlc.2025.04.073","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages e143-e144"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Deep Sternal Wound Infection on Long-Term Survival Based on Revascularisation Strategy: Results From the Polish National Registry 基于血运重建策略的深胸骨伤口感染对长期生存的影响:来自波兰国家登记处的结果。
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.03.016
Sleiman Sebastian Aboul-Hassan MD, PhD , Grzegorz Hirnle MD, PhD , Bartlomiej Perek MD, PhD , Marek Jemielity MD, PhD , Szymon Kocanda MD, PhD , Tomasz Hirnle MD, PhD , Miroslaw Brykczynski MD, PhD , Radoslaw Gocol MD, PhD , Marek Deja MD, PhD , Jan Rogowski MD, PhD , Michal Krejca MD, PhD , Wojciech Pawliszak MD, PhD , Kazimierz Widenka MD, PhD , Jerzy Pacholewicz MD, PhD , Pawel Bugajski MD, PhD , Krzysztof Wrobel MD, PhD , Bohdan J. Maruszewski MD, PhD , Tomasz Hrapkowicz MD, PhD , Romuald Cichon MD, PhD , KROK Investigators
{"title":"Impact of Deep Sternal Wound Infection on Long-Term Survival Based on Revascularisation Strategy: Results From the Polish National Registry","authors":"Sleiman Sebastian Aboul-Hassan MD, PhD ,&nbsp;Grzegorz Hirnle MD, PhD ,&nbsp;Bartlomiej Perek MD, PhD ,&nbsp;Marek Jemielity MD, PhD ,&nbsp;Szymon Kocanda MD, PhD ,&nbsp;Tomasz Hirnle MD, PhD ,&nbsp;Miroslaw Brykczynski MD, PhD ,&nbsp;Radoslaw Gocol MD, PhD ,&nbsp;Marek Deja MD, PhD ,&nbsp;Jan Rogowski MD, PhD ,&nbsp;Michal Krejca MD, PhD ,&nbsp;Wojciech Pawliszak MD, PhD ,&nbsp;Kazimierz Widenka MD, PhD ,&nbsp;Jerzy Pacholewicz MD, PhD ,&nbsp;Pawel Bugajski MD, PhD ,&nbsp;Krzysztof Wrobel MD, PhD ,&nbsp;Bohdan J. Maruszewski MD, PhD ,&nbsp;Tomasz Hrapkowicz MD, PhD ,&nbsp;Romuald Cichon MD, PhD ,&nbsp;KROK Investigators","doi":"10.1016/j.hlc.2025.03.016","DOIUrl":"10.1016/j.hlc.2025.03.016","url":null,"abstract":"<div><h3>Background</h3><div>This multicentre study aimed to investigate the impact of deep sternal wound infection (DSWI) on long-term survival among patients undergoing coronary artery bypass grafting (CABG) using multiple arterial grafting (MAG) or single artery with saphenous vein grafts (SAG).</div></div><div><h3>Methods</h3><div>Data were obtained from the Polish National Registry of Cardiac Surgery Procedures database. Between January 2012 and December 2020, 81,136 patients who underwent CABG for multivessel disease were included in the study. Patients were divided into four groups: MAG with DSWI (n=219), MAG without DSWI (n=8,611), SAG with DSWI (n=1,432), and SAG without DSWI (n=70,874). Inverse probability of treatment weighting based on the generalised propensity score was used to minimise imbalance between the groups.</div></div><div><h3>Results</h3><div>In the weighted sample, DSWI in patients who received MAG was associated with reduced long-term survival when compared with patients without DSWI and MAG (hazard ratio [HR] 1.89, 95% confidence interval [CI] 1.29–2.78; Bonferroni corrected p=0.01). Deep sternal wound infection in patients who received SAG was associated with reduced long-term survival when compared with patients without DSWI and SAG (HR 1.92, 95% CI 1.69–2.17; Bonferroni corrected p=0.01). In patients who did not develop DSWI, MAG was associated with improved long-term survival compared with SAG (HR 0.68, 95% CI 0.63–0.74; Bonferroni corrected p=0.01). However, patients who received MAG and developed DSWI had similar long-term survival when compared with patients who received SAG and did not develop DSWI (HR 1.31, 95% CI 0.90–1.92; Bonferroni corrected p=0.63). A landmark analysis excluding the first 6 months of follow-up was performed to exclude the risk of acute mortality due to DSWI. In the weighted sample, the results were consistent with the main analysis.</div></div><div><h3>Conclusion</h3><div>Deep sternal wound infection is associated with worse survival in patients receiving MAG and SAG. Moreover, the superior effect of MAG over SAG diminishes once DSWI develops.</div></div>","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 961-968"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis 急性心肌梗死、超重或肥胖无糖尿病患者服用2.4 mg西马鲁肽的资格:一项现实世界分析
IF 2.2 4区 医学
Heart, Lung and Circulation Pub Date : 2025-09-01 DOI: 10.1016/j.hlc.2025.01.011
Rahil Ajmera MBBS , Hassan Karim MBBS , P. Gerry Fegan MD, FRACP , Girish Dwivedi MD, PhD, FRACP , Nick S.R. Lan MBBS, MClinRes, FRACP
{"title":"Eligibility for Semaglutide 2.4 mg in Patients With Acute Myocardial Infarction and Overweight or Obesity Without Diabetes: A Real-World Analysis","authors":"Rahil Ajmera MBBS ,&nbsp;Hassan Karim MBBS ,&nbsp;P. Gerry Fegan MD, FRACP ,&nbsp;Girish Dwivedi MD, PhD, FRACP ,&nbsp;Nick S.R. Lan MBBS, MClinRes, FRACP","doi":"10.1016/j.hlc.2025.01.011","DOIUrl":"10.1016/j.hlc.2025.01.011","url":null,"abstract":"","PeriodicalId":13000,"journal":{"name":"Heart, Lung and Circulation","volume":"34 9","pages":"Pages 977-979"},"PeriodicalIF":2.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144077057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信